Market Access News | pharmaphorum

News

CHMP backs Biogen’s Skyclarys for Friedreich’s ataxia

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended

News

NICE’s new cholesterol guidance looks beyond statins

NICE has set a new target for cholesterol levels in people who have had a heart attack or stroke to reduce the risk of them having another, encouraging the use of addition

News

MSD claims 2nd FDA approval for Welireg, in kidney cancer

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f

News

Hemgenix first drug to clear France’s ‘direct access’ route

CSL Behring’s haemophilia B gene therapy Hemgenix has become the first drug to be authorised for use under France’s recently-introduced ‘direct access’ programme, which ai

News

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)

News

SCOTUS will rule on abortion pill access in landmark case

The Supreme Court of the US has said it will consider a lower court ruling that would restrict access to the abortion pill mifepristone and is considered to be tied to the

CHMP backs Biogen’s Skyclarys for Friedreich’s ataxia

NICE’s new cholesterol guidance looks beyond statins

MSD claims 2nd FDA approval for Welireg, in kidney cancer

Hemgenix first drug to clear France’s ‘direct access’ route

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

SCOTUS will rule on abortion pill access in landmark case

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks